Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19

Background Use of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARB) is thought to affect COVID‐19 through modulating levels of angiotensin‐converting enzyme 2, the cell entry receptor for SARS‐CoV2. We sought to assess the association between ACEi/ARB, biomarkers...

Full description

Bibliographic Details
Main Authors: Michael Pan, Alexi Vasbinder, Elizabeth Anderson, Toniemarie Catalan, Husam R. Shadid, Hanna Berlin, Kishan Padalia, Patrick O’Hayer, Chelsea Meloche, Tariq U. Azam, Ibrahim Khaleel, Erinleigh Michaud, Pennelope Blakely, Abbas Bitar, Yiyuan Huang, Lili Zhao, Rodica Pop‐Busui, Sven H. Loosen, Athanasios Chalkias, Frank Tacke, Evangelos J. Giamarellos‐Bourboulis, Jochen Reiser, Jesper Eugen‐Olsen, Salim S. Hayek
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
ACE inhibitors
angiotensin receptor blockers
COVID‐19
mortality
outcomes
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.023535

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.023535

Similar Items